中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)

Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer(2021 edition)

中国肺癌的发病率和死亡率均位于恶性肿瘤中的第1位。为进一步规范中国肺癌防治措施、提高肺癌的诊疗水平、改善患者的预后、为各级临床医务人员提供专业的循证医学意见,中华医学会肿瘤学分会组织呼吸内科、肿瘤内科、胸外科、放疗科、影像科和病理科专家,结合国际指南推荐意见和中国临床实践现状,整合近年来肺癌病理、基因检测、免疫分子标志物检测和治疗手段等方面的最新循证医学证据,经过共识会议制定了中华医学会肿瘤学分会肺癌临床诊疗指南(2021版),旨在为各级临床医师、影像、检验、康复等专业人员提供肺癌筛查、诊断、病理、治疗和随访等方面的推荐意见。

In China,the incidence and mortality of lung cancer are ranked the first among malignant tumors.In order to further standardize the prevention and treatment measures of lung cancer,improve the prognosis of patients,and provide professional evidence-based medical recommendations to clinical medical staffs,Oncology Society of Chinese Medical Association organized experts from departments of pulmonary medicine,oncology,thoracic surgery,radiotherapy,imaging and pathology,based on the international guidelines and clinical practices in China,integrated the latest evidence-based medical evidences in lung cancer pathology,genetic testing,immune molecular marker detection and treatment methods in recent years.After consensus meetings,the Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer in China was conducted,which provided recommendations of lung cancer screening,diagnosis,pathology,treatment and follow-up to clinicians,imaging,laboratory,and rehabilitation professionals.